Nicholas Piramal acquires Anafortan for Rs 116 cr

New Delhi, Apr 15 (UNI) Pharma major Nicholas Piramal India Ltd (NPIL) today said it has signed an agreement for purchase of Anafortan and CEFI Brand Groups of K-Lab for Rs 116 crore.

As a part of the agreement, K-Lab has agreed to provide NPIL with certain patents' use and non-compete assurances for Cefixime and Camylofin based drugs, the company said in a statement.

Anafortan and CEFI Groups had Revenues of Rs 49.1 crore and EBIDTA of Rs 20.7 crore for the financial year ended March 31, 2008.

''We are delighted to acquire the CEFI and Anafortan Brand Groups from K-Lab. CEFI and Anafortan offer unique therapeutic value to patients, which we hope to offer to patients across India with our national sales and distribution network,'' said Nicholas Piramal Chairman Ajay Piramal.

UNI AK PBB AS2020